In the last few weeks I have talked with numerous colleagues about the findings from LATITUDE and STAMPEDE presented recently at the ASCO Annual Meeting and published in the New England Journal of Medicine in June 2017. We find ourselves in the process of integrating the findings into a treatment landscape that is still grappling with the findings of CHAARTED, data demonstrating a survival benefit from the use of chemohormonal therapy in a similar high risk population of men with metastatic hormone sensitive prostate cancer (mHSPC) first presented only a few years ago.
For nearly the past decade, I have studied complications of cancer survivorship and how patients might better integrate this information into their treatment decisions. Most of this has centered on complications of hormonal therapy for men with prostate cancer, with an emphasis on assessing complications from the patient prospective using patient reported outcome measures, in addition to objective scientific measures like the CTCAE.
In my day-to-day practice caring for men with prostate cancer, questions about testosterone come up daily. Men wonder if they have too little testosterone, had too much testosterone exposure, and if they can get their testosterone back if they are receiving androgen deprivation therapy. One concern that men with a history of using supplemental testosterone bring up routinely is whether exposure to this additional testosterone increased their risk for prostate cancer.
Goal: To serve as an interface between community urologists, medical oncologists, radiation oncologists, advanced practice providers, and specialty nurses to remain updated on best practices, areas of controversy, and the latest advances in the care of advanced prostate cancer patients.